Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 in Orkambi-treated Cystic Fibrosis
NCT03474042Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GLPG2737 in cystic fibrosis (CF), sponsored by Galapagos NV. Started Nov 2017; status: completed.
02
Drugs
GLPG2737
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03474042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474042.